©The Author(s) 2026.
World J Diabetes. Feb 15, 2026; 17(2): 112859
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112859
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112859
Figure 5 Nomogram model and results of decision curve analysis for quantifying the individual risk of diabetic gastric autonomic neuropathy in patients with type 2 diabetes mellitus.
A: The nomogram includes age, fasting C-peptide, and taurolithocholic acid along with their corresponding points and total risk scores; B: Decision curve analysis was performed to evaluate the clinical net benefit across different risk thresholds. TLCA: Taurolithocholic acid; FC-P: Fasting C-peptide; DGAN: Diabetic gastric autonomic neuropathy.
- Citation: Zhu KY, Wang SJ, Li J, Ma PP, Feng SS, Guo L, Lu YB, Dong L, Ding DF. Association of serum bile acid profiles with the risk of gastrointestinal autonomic neuropathy in patients with type 2 diabetes mellitus. World J Diabetes 2026; 17(2): 112859
- URL: https://www.wjgnet.com/1948-9358/full/v17/i2/112859.htm
- DOI: https://dx.doi.org/10.4239/wjd.v17.i2.112859